Fullerton Fund Management Co Ltd. Boosts Stock Position in Teva Pharmaceutical Industries Ltd. $TEVA

Fullerton Fund Management Co Ltd. increased its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 35.5% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 117,949 shares of the company’s stock after purchasing an additional 30,920 shares during the quarter. Fullerton Fund Management Co Ltd.’s holdings in Teva Pharmaceutical Industries were worth $1,977,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the stock. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its position in shares of Teva Pharmaceutical Industries by 0.5% during the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 118,209 shares of the company’s stock valued at $1,981,000 after buying an additional 615 shares during the period. US Bancorp DE increased its holdings in Teva Pharmaceutical Industries by 6.5% during the 1st quarter. US Bancorp DE now owns 10,812 shares of the company’s stock worth $166,000 after acquiring an additional 656 shares during the period. MAI Capital Management boosted its holdings in Teva Pharmaceutical Industries by 26.8% in the 2nd quarter. MAI Capital Management now owns 3,293 shares of the company’s stock valued at $55,000 after purchasing an additional 697 shares during the period. Wedbush Securities Inc. boosted its holdings in Teva Pharmaceutical Industries by 3.3% in the 2nd quarter. Wedbush Securities Inc. now owns 21,995 shares of the company’s stock valued at $369,000 after purchasing an additional 700 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in shares of Teva Pharmaceutical Industries by 15.0% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,474 shares of the company’s stock valued at $92,000 after purchasing an additional 715 shares in the last quarter. Institutional investors own 54.05% of the company’s stock.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Mark Sabag sold 216,892 shares of the firm’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $28.73, for a total value of $6,231,307.16. Following the sale, the insider owned 52,828 shares of the company’s stock, valued at $1,517,748.44. This trade represents a 80.41% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Roberto Mignone sold 200,000 shares of the company’s stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $24.11, for a total transaction of $4,822,000.00. Following the transaction, the director directly owned 495,000 shares of the company’s stock, valued at approximately $11,934,450. This trade represents a 28.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 532,360 shares of company stock worth $14,364,929. Insiders own 0.49% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on TEVA. The Goldman Sachs Group boosted their target price on Teva Pharmaceutical Industries from $28.00 to $31.00 and gave the stock a “buy” rating in a research report on Monday, December 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, October 8th. Bank of America lifted their target price on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday. Scotiabank initiated coverage on shares of Teva Pharmaceutical Industries in a research report on Friday, December 5th. They set a “sector outperform” rating and a $35.00 price objective on the stock. Finally, Wall Street Zen lowered shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Three equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $30.25.

Teva Pharmaceutical Industries Price Performance

TEVA opened at $29.80 on Friday. The company has a debt-to-equity ratio of 2.31, a current ratio of 1.11 and a quick ratio of 0.82. The stock’s 50 day simple moving average is $23.43 and its 200 day simple moving average is $19.60. The firm has a market cap of $34.18 billion, a price-to-earnings ratio of 49.67, a PEG ratio of 1.79 and a beta of 0.67. Teva Pharmaceutical Industries Ltd. has a 1 year low of $12.47 and a 1 year high of $30.20.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.